Related Experiment Video

Updated: Mar 3, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.4K

Glycemic control, including Time in Tight Range (TITR) evaluation, in children with type 1 diabetes treated with the

Mateusz Tarasiewicz1, Wiktoria Bartnikowska1, Agata Chobot2

  • 1Department of Children's Diabetology and Lifestyle Medicine, Medical University of Silesia, Katowice, Poland.

Frontiers in Endocrinology
|March 2, 2026
PubMed

Insights

The MiniMed 780G automated insulin delivery system maintained optimal glycemic control in children with type 1 diabetes over three years, with auto-correction boluses proving beneficial.

Area of Science:

  • Pediatrics
  • Endocrinology
  • Medical Technology

Background:

  • The MiniMed 780G is the first automated insulin delivery (AID) system commercially available in Poland.
  • Type 1 diabetes (T1D) management in children requires continuous monitoring and adjustment of insulin delivery.

Purpose of the Study:

  • To analyze glycemic management in children with T1D using the MiniMed 780G AID system over a three-year period.
  • To evaluate the long-term effectiveness of AID technology in pediatric T1D patients.

Main Methods:

  • A cohort of fifty children with T1D using the MiniMed 780G system were analyzed.
  • Data collected included anthropometric measurements, insulin pump data, and continuous glucose monitoring (CGM) at baseline, 12 months, and 36 months.

Main Results:

  • Glycemic control, measured by time in range (TIR), showed a slight decrease after three years but remained within optimal levels.
  • The percentage of auto-correction boluses in the total daily insulin dose significantly increased over the three years.
  • Coefficient of variation (CV) and BMI z-scores remained stable, indicating consistent metabolic control.

Conclusions:

  • The MiniMed 780G system facilitates optimal glycemic management in children with T1D over three years.
  • Auto-correction features likely contribute to maintaining recommended glycemic metrics, even with slight deteriorations over time.
Abstract

Keywords:
automated insulin deliverychildrendiabetesdiabetes mellitustime in tight rangetype 1 diabetes

More Related Videos

Simple Continuous Glucose Monitoring in Freely Moving Mice03:25

Simple Continuous Glucose Monitoring in Freely Moving Mice

Published on: February 24, 2023

8.2K
Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

1.1K

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.2K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
952
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.7K
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.5K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.1K